Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. News
  7. Summary
    RNO   AU000000RNO1

RHINOMED LIMITED

(RNO)
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/22
0.315 AUD   +5.00%
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
10/19PRESS RELEASE : New swab takes away children's fear of swabbing
DJ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rhinomed Limited Receives Purchase Orders and Begun Supplying NSW Health Pathology

08/10/2021 | 08:08pm EDT

Rhinomed Limited has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability. The company has commenced deliveries with these initial orders being fulfilled over coming weeks. Rhinomed is now scaling up its manufacturing facilities to respond to growing domestic and international demand for this innovative technology. Rhinomed has leveraged its deep expertise in wearable nasal medical devices to develop a novel nasal swab that is easier, and more comfortable to use. Interim results from a recent comparison study (n= 204) being completed at CWZ and Radboud University Medical Center, a leading teaching hospital in Nijmegen in the Netherlands are in line with the previously announced user study results and showed participants' strong preference for the Rhinoswab when compared to the traditional nasal swab: 89% of respondents preferred Rhinoswab to the Nasopharyngeal swab;98% of respondents felt no pain with Rhinoswab vs 48% with Nasopharyngeal swab; 98% of respondents needed little or no guidance when using RhinoswabTM.


© S&P Capital IQ 2021
All news about RHINOMED LIMITED
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
10/19PRESS RELEASE : New swab takes away children's fear of swabbing
DJ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
CI
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
MT
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
CI
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
CI
08/26Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/10Rhinomed Limited Receives Purchase Orders and Begun Supplying NSW Health Pathology
CI
05/20RHINOMED : Receives CE Mark for Nasal Swab Product
MT
More news
Financials
Sales 2021 4,42 M 3,30 M 3,30 M
Net income 2021 -8,64 M -6,45 M -6,45 M
Net cash 2021 1,87 M 1,40 M 1,40 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 79,9 M 59,7 M 59,7 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 10,1%
Chart RHINOMED LIMITED
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors